your partner in preclinical research



Urosphere team owns scientific knowledge, strong expertise and experience to build a trustworthy relationship with our partners and to provide the highest quality services.

Management team

+ Philippe Lluel, PH.D. – CEO, founder

Philippe has more than 20 years of research and management positions in the pharmaceutical industry. He has extensive experience in drug discovery in urological field (mainly BPH, urinary incontinence, overactive bladder, kidney pathologies and aging). He was involved in all aspects of drug development from discovery through registration. Philippe’s personal research interests have focused on the development of improved in vivo experimental models to facilitate the translation from preclinical to clinical studies. Philippe received his Ph.D. in Pharmacology from Pierre et Marie Curie University (Paris, France). He is the author of 25 peer-reviewed publications. 


+ Sophie Chabot, PH.D. – COO

Sophie joined the Pasteur Institute (Paris, France) in 1998. She received her Ph.D. in Physiological and Pathophysiological Sciences 4 years later. After a first post-doc in the Scripps Research Institute (La Jolla, USA), Sophie returned to France to work in academic institutions (Inserm U563 and CNRS UMR5089) in Toulouse. Starting from projects in inflammation, her research quickly turned to oncology. Sophie is Chief Operating Officer, she is also responsible at Urosphere for managing in vivo studies in the field of inflammation, pain and cancer.


+ Yolande Misseri, PH.D., L.L.M. – CDO

Yolande has over 15 years of research and management positions in the biotech industry. She has extensive experience in drug discovery in the immuno-oncology field, intellectual property and business. She has been involved in drug development from discovery to clinical phases at BT PHARMA as project leader and at GENTICEL as Intellectual Property Director until 2016. She has then developed her expertise in strategic management of IP and alliances as a Consultant before joining UROLEAD end of 2018. Yolande’s personal interests are focused on the development of innovative preclinical solutions and new partnerships to facilitate the translation from preclinical to clinical studies. Yolande received her Ph.D. in Biology from the University of Montpellier II (Montpellier, France). She completed her scientific knowledge with a Master of Management of the Biotechnology at Toulouse Business School (Toulouse, France) and with a Master of Intellectual Property Law and Management at CEIPI (Strasbourg, France).


Scientific staff

+ Chiara Alfarano – PH.D., Pharm.D

Chiara received her Ph.D. degree in Pathophysiology and Clinical Aging from Florence University (Italy) in 2008. Between 2008 and 2011, she worked as post-doctoral research Scientist on kidney fibrosis after ischemia-reperfusion. During 5 years, Chiara had an academic experience in Nephrology (INSERM U1048 / I2MC) in Toulouse. Chiara joined Urosphere in 2013. She is in charge of in vivo nephrology unit.


+ Claire Beraud – Ph.D., Pharm. D

Claire has over 10 years of research experience in the field of oncology. She had an initial education in pharmaceutical sciences in Toulouse (France). Then, she joined the Curie Institute (Paris, France) in 2004 and received her PhD degree in molecular and cellular biology 4 years later. Between 2009/2010, she worked as a post doc research scientist on renal cell carcinoma in Strasbourg (Inserm U682). She has developed and characterized Urolead PDX models since 2010.


+ Véronique Guilloteau – PH.D.

Véronique received her Ph.D. degree in Animal physiology and pharmacology from Paul Sabatier University (Toulouse, France) in 1996. Then, she had an academic experience in visceral pain (neurophysiology) in the University of Iowa (IA, USA). Back to France, Véronique held a position of senior scientist in gastrointestinal department at Pfizer based in Paris. In 2004, Véronique worked as Project Manager in Pelvipharm. In 2007, Veronique joined Urosphere as Project Manager. She is now in charge of functional urology unit.


+ Myriam Lassalle – MSc. Ing.

Myriam has over 12 years of research experience in the field of oncology. With a Master of Engineering in biotechnology obtained in 2003 at the institute of technology of Bordeaux (IPB / ENSTBB, France), she firstly had a Research Engineer position at Theraptosis (Pasteur Institute, Paris) for 4 years, where she produced antibodies directed against cancer and analyzed their apoptotic potential on cancer cells. Then she acquired an extensive knowledge of in vivo PDX studies and of project management at XenTech, as Study Director for 9 years. After a Clinical Research Associate Course, she joined Urosphere on September 2015, where she is in charge of developing urogenital PDX models at Urosphere and of managing in vivo cancer studies.


+ Murielle Méen – PH.D.

Murielle completed her Ph.D. in Neuropharmacology in 2001 at Blaise Pascal University (France). She worked for two years as a post-doctoral research Scientist at Grünenthal GmbH (Aachen, Germany) on behavioral pain models using in vivo experiments. Murielle joined Urosphere in 2005, where she was involved in in vivo experimentations. In 2010, Murielle followed training courses in experimental surgery at the National Veterinary School of Lyon (France). Since 2013, Murielle is in charge of animal’s ethics and is currently member of the ethics committee CEEA-122. 


+ Moèz Rekik – PH.D.

Moèz joined Urosphere in 2005 as Laboratory Manager. Moèz received a Ph.D. in gastrointestinal Pharmacology from Paul Sabatier University (Toulouse, France), then moved to school of Medicine of East Carolina University (NC, USA) as Researcher and instructor in Cardiovascular Pharmacology. Back to France, Moèz held a position of Project Manager in Safety Pharmacology at Porsolt and Partners Pharmacology, a French preclinical CRO based in Paris. Over the last two years, Moèz is responsible for the implementation, development and certification of Urosphere Quality Management System in accordance with ISO9001 standards. In addition to his line management responsibility, Moèz is part of Urosphere scientific in vitro Pharmacology experts.


+ Céline Rouget – PH.D.

Céline received her Ph.D. degree in Experimental and Clinical Pharmacology from René Descartes Paris V University in 2004. She has an academic experience in functional studies on isolated tissues and she worked as scientist researcher at the Sanofi-Aventis research center in Milan (Italy). Céline joined Urosphere in 2009. She is in charge of the in vitro pharmacology department and is responsible for coordinating in vitro efficacy studies in animal and human isolated tissues.